- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06267313
Attention Training for COVID-19 Related Distress
April 1, 2024 updated by: Mikael Rubin, Palo Alto University
The study aims to test whether attention training (attention bias modification or attention control training) reduces distress or COVID-19 related anxiety compared to a neutral condition.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mikael Rubin, PhD
- Phone Number: 650-433-3805
- Email: mrubin@paloaltou.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Recruiting
- Palo Alto University
-
Contact:
- Mikael Rubin, PhD
- Phone Number: 650-433-3805
- Email: mrubin@paloaltou.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- COVID-19 Anxiety Syndrome Scale > 7 and/or COVID-19 related loss
Exclusion Criteria:
- Does not speak English Fluently
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Attention Bias Modification
|
Training attention away from threat
|
Active Comparator: Attention Control Training
|
Training attention control
|
Placebo Comparator: Neutral Training
|
Attention training with Neutral stimuli
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
COVID-19 Anxiety Syndrome Scale
Time Frame: 0 days
|
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
|
0 days
|
COVID-19 Anxiety Syndrome Scale
Time Frame: 21 days
|
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
|
21 days
|
COVID-19 Anxiety Syndrome Scale
Time Frame: 49 days
|
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
|
49 days
|
COVID-19 Anxiety Syndrome Scale
Time Frame: 105 days
|
The measure is scored using a 5-point time anchored scale (0 = Not at all to 4 = Nearly every day over the last 2 weeks) and scores range between 0 and 20, with higher scores reflecting worse outcome.
|
105 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 19, 2024
Primary Completion (Estimated)
February 19, 2027
Study Completion (Estimated)
February 19, 2027
Study Registration Dates
First Submitted
February 17, 2024
First Submitted That Met QC Criteria
February 17, 2024
First Posted (Actual)
February 20, 2024
Study Record Updates
Last Update Posted (Actual)
April 2, 2024
Last Update Submitted That Met QC Criteria
April 1, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- 2023-078-PAU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
IPD will be made available with accompanying manuscript
IPD Sharing Time Frame
Analytic code will be shared with accompanying manuscript
IPD Sharing Supporting Information Type
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on Attention Bias Modification
-
University of Texas at AustinArcade TherapeuticsNot yet recruiting
-
University of OsloDiakonhjemmet Hospital; University of Oxford; ExtrastiftelsenCompletedMajor Depressive DisorderNorway
-
University of OsloDiakonhjemmet Hospital; University of Oxford; Sorlandet Hospital HFCompleted
-
University of Texas at TylerPsi Chi; Sarah Sass, PhDRecruiting
-
Florida State UniversitySan Diego State UniversityCompleted
-
Hunan Normal UniversityCompletedDepressive Disorder, MajorChina
-
University of Nebraska LincolnCompletedPosttraumatic Stress DisorderUnited States
-
Virginia Polytechnic Institute and State UniversityCompleted
-
Umeå UniversityCompleted
-
Humboldt-Universität zu BerlinCompletedObsessive-Compulsive DisorderGermany